HF
ITOS

HRT Financial’s iTeos Therapeutics ITOS Stock Holding History

HRT Financial’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,964
Closed -$191K – 2936
2024
Q4 		$191K Sell
24,964
-33,486
-57% -$288K ﹤0.01% 1950
2024
Q3 		$596K Buy
+58,450
New +$892K ﹤0.01% 1506
2024
Q2 		– Sell
-50,936
Closed -$694K – 2635
2024
Q1 		$694K Sell
50,936
-7,680
-13% -$83.7K ﹤0.01% 1076
2023
Q4 		$641K Buy
+58,616
New +$581K ﹤0.01% 1231
2022
Q3 		– Sell
-10,714
Closed -$220K – 3150
2022
Q2 		$220K Buy
+10,714
New +$254K ﹤0.01% 2207
2021
Q3 		– Sell
-14,315
Closed -$367K – 3502
2021
Q2 		$367K Buy
+14,315
New +$341K ﹤0.01% 2013

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HRT Financial's ITOS Position: Q1 2025 in Review

HRT Financial sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 24,964 shares — an estimated $191K sold.

HRT Financial first reported a position in ITOS in Q2 2021 and held it in 6 quarters. The position peaked at $694K in Q1 2024. 131 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.

  • HRT Financial reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 24,964 iTeos Therapeutics shares in Q1 2025, an estimated $191K.
  • HRT Financial first reported a position in iTeos Therapeutics in Q2 2021 and held it in 6 quarters.
  • HRT Financial's iTeos Therapeutics position peaked at $694K in Q1 2024.
  • 131 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.